Comprehensive immunohistochemical analysis reveals ADC target expression dynamics in endometrial and cervical cancers, suggesting new therapeutic avenues.
Antibody–drug conjugates (ADCs) are emerging as an important therapeutic strategy in gynecologic malignancies. However, comprehensive characterization of ADC target expression across histologic subtypes of endometrial cancer (EC) and cervical cancer (CC), and their temporal dynamics, remains limited.
No takes yet. Share an insight, caveat, or question.
Shin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: